User login
Forget Fibrates for Cardiovascular Risk Reduction: Commentary on the Failure and Implications of the PROMINENT Trial
In this supplement to Family Medicine, Charles P Vega, MD, and Pamela R Kushner, MD, discuss failure of the PROMINENT trial and implications for use of fibrates to reduce cardiovascular risk.
In this supplement to Family Medicine, Charles P Vega, MD, and Pamela R Kushner, MD, discuss failure of the PROMINENT trial and implications for use of fibrates to reduce cardiovascular risk.
In this supplement to Family Medicine, Charles P Vega, MD, and Pamela R Kushner, MD, discuss failure of the PROMINENT trial and implications for use of fibrates to reduce cardiovascular risk.
Mycoplasma genitalium: A Pathogen We Can Finally Begin to Understand
Riding alongside known STIs, this historically elusive microbe may have often been the underlying cause of a variety of symptoms. In this supplement to OBG Management Dr. Kyle Bukowski discusses how to meet the challenge presented by this not-so-new microbe while helping foster regular STI testing, and encourage patients to seek care when symptoms occur.
Riding alongside known STIs, this historically elusive microbe may have often been the underlying cause of a variety of symptoms. In this supplement to OBG Management Dr. Kyle Bukowski discusses how to meet the challenge presented by this not-so-new microbe while helping foster regular STI testing, and encourage patients to seek care when symptoms occur.
Riding alongside known STIs, this historically elusive microbe may have often been the underlying cause of a variety of symptoms. In this supplement to OBG Management Dr. Kyle Bukowski discusses how to meet the challenge presented by this not-so-new microbe while helping foster regular STI testing, and encourage patients to seek care when symptoms occur.
Frontline STI Screening Starts with Primary Care
In this supplement to Family Practice, Heather M. Territo, MD, and Gale R. Burstein, MD, MPH discuss how primary care physicians play an essential role in screening for STIs in young patients.
In this supplement to Family Practice, Heather M. Territo, MD, and Gale R. Burstein, MD, MPH discuss how primary care physicians play an essential role in screening for STIs in young patients.
In this supplement to Family Practice, Heather M. Territo, MD, and Gale R. Burstein, MD, MPH discuss how primary care physicians play an essential role in screening for STIs in young patients.
Non-Surgical Treatment of Heavy Menstrual Bleeding From Fibroids: A New Paradigm
GnRH antagonists with estrogen/progesterone are promising new uterine-sparing options for treating uterine fibroids. Two experts review data from two recent clinical trials to bring you up to speed on the benefits and risks of this treatment approach.
After reading this short article, you have an opportunity to earn 1.0 CME credits.
GnRH antagonists with estrogen/progesterone are promising new uterine-sparing options for treating uterine fibroids. Two experts review data from two recent clinical trials to bring you up to speed on the benefits and risks of this treatment approach.
After reading this short article, you have an opportunity to earn 1.0 CME credits.
GnRH antagonists with estrogen/progesterone are promising new uterine-sparing options for treating uterine fibroids. Two experts review data from two recent clinical trials to bring you up to speed on the benefits and risks of this treatment approach.
After reading this short article, you have an opportunity to earn 1.0 CME credits.
We Have the Tools to Prevent Cervical Cancer— So Why Are Rates Increasing?
Cervical cancer screening is often hailed as the most successful screening program ever implemented. Despite these past successes, cervical cancer incidence is no longer decreasing and is actually rising significantly in younger women within the United States. In a country with a well-established screening program, effective screening tools, and HPV vaccination, it seems unfathomable that we are witnessing an increase in cervical cancers. This alarming trend should be cause for concern among all healthcare professionals.
Cervical cancer screening is often hailed as the most successful screening program ever implemented. Despite these past successes, cervical cancer incidence is no longer decreasing and is actually rising significantly in younger women within the United States. In a country with a well-established screening program, effective screening tools, and HPV vaccination, it seems unfathomable that we are witnessing an increase in cervical cancers. This alarming trend should be cause for concern among all healthcare professionals.
Cervical cancer screening is often hailed as the most successful screening program ever implemented. Despite these past successes, cervical cancer incidence is no longer decreasing and is actually rising significantly in younger women within the United States. In a country with a well-established screening program, effective screening tools, and HPV vaccination, it seems unfathomable that we are witnessing an increase in cervical cancers. This alarming trend should be cause for concern among all healthcare professionals.
Fourth Study to Show Consistent Benefit of Highly Purified Eicosapentaenoic Acid on Cardiovascular Outcomes: Results From RESPECT-EPA
In this supplement to Cardiology News, John R. Nelson, MD, FACC, FNLA, FASNC, and Matthew J. Budoff, MD, discuss results from RESPECT-EPA and the existing evidence that purified eicosapentaenoic acid significantly reduces residual CV risk in patients with CVD.
In this supplement to Cardiology News, John R. Nelson, MD, FACC, FNLA, FASNC, and Matthew J. Budoff, MD, discuss results from RESPECT-EPA and the existing evidence that purified eicosapentaenoic acid significantly reduces residual CV risk in patients with CVD.
In this supplement to Cardiology News, John R. Nelson, MD, FACC, FNLA, FASNC, and Matthew J. Budoff, MD, discuss results from RESPECT-EPA and the existing evidence that purified eicosapentaenoic acid significantly reduces residual CV risk in patients with CVD.
“The Nail in the Coffin for Fibrates”: Futility of PROMINENT Trial Definitively Settles Debate on Avoiding Use of Fibrate Class of Medications for Cardiovascular Risk Reduction
In this supplement to Cardiology News, Payal Kohli, MD, FACC, and Nihar Desai, MD, MPH, discuss the PROMINENT trial and the debate on avoiding the use of fibrates for cardiovascular risk reduction.
In this supplement to Cardiology News, Payal Kohli, MD, FACC, and Nihar Desai, MD, MPH, discuss the PROMINENT trial and the debate on avoiding the use of fibrates for cardiovascular risk reduction.
In this supplement to Cardiology News, Payal Kohli, MD, FACC, and Nihar Desai, MD, MPH, discuss the PROMINENT trial and the debate on avoiding the use of fibrates for cardiovascular risk reduction.
Perspectives on Hypercortisolism Diagnosis and Management in Community and Academic Centers
Lewis Blevins, MD; Richard Auchus, MD, PhD; David Brown, MD, PhD; Amir Hamrahian, MD; and Smita Kargutkar, MD share their insights and real-world perspectives on hypercortisolism diagnosis and management, including:
• The understanding of hypercortisolism has evolved significantly over the past decades to extend beyond classic physical manifestations (e.g., central obesity, facial plethora, buffalo hump, purple striae)
• Early identification of patients with mild autonomous cortisol secretion is important as hypercortisolism can lead to age-inappropriate and treatment-resistant metabolic syndrome
• Patient identification and management approaches for hypercortisolism can differ between academic and community settings due to differences in available resources and multidisciplinary management teams
• Educating primary care providers and community endocrinologists about the consequences of hypercortisolism can be beneficial in bridging the gap between academic and community settings
 Lewis Blevins, MD |  Richard Auchus, MD, PhD
|  David Brown, MD, PhD
|
 Amir Hamrahian, MD |  Smita Kargutkar, MD |
Click HERE to read the supplement.
©2022 Corcept Therapeutics Incorporated. All Rights Reserved. DSE-00997 DEC 2022
Lewis Blevins, MD; Richard Auchus, MD, PhD; David Brown, MD, PhD; Amir Hamrahian, MD; and Smita Kargutkar, MD share their insights and real-world perspectives on hypercortisolism diagnosis and management, including:
• The understanding of hypercortisolism has evolved significantly over the past decades to extend beyond classic physical manifestations (e.g., central obesity, facial plethora, buffalo hump, purple striae)
• Early identification of patients with mild autonomous cortisol secretion is important as hypercortisolism can lead to age-inappropriate and treatment-resistant metabolic syndrome
• Patient identification and management approaches for hypercortisolism can differ between academic and community settings due to differences in available resources and multidisciplinary management teams
• Educating primary care providers and community endocrinologists about the consequences of hypercortisolism can be beneficial in bridging the gap between academic and community settings
Lewis Blevins, MD | Richard Auchus, MD, PhD
| David Brown, MD, PhD
|
Amir Hamrahian, MD | Smita Kargutkar, MD |
Click HERE to read the supplement.
©2022 Corcept Therapeutics Incorporated. All Rights Reserved. DSE-00997 DEC 2022
Lewis Blevins, MD; Richard Auchus, MD, PhD; David Brown, MD, PhD; Amir Hamrahian, MD; and Smita Kargutkar, MD share their insights and real-world perspectives on hypercortisolism diagnosis and management, including:
• The understanding of hypercortisolism has evolved significantly over the past decades to extend beyond classic physical manifestations (e.g., central obesity, facial plethora, buffalo hump, purple striae)
• Early identification of patients with mild autonomous cortisol secretion is important as hypercortisolism can lead to age-inappropriate and treatment-resistant metabolic syndrome
• Patient identification and management approaches for hypercortisolism can differ between academic and community settings due to differences in available resources and multidisciplinary management teams
• Educating primary care providers and community endocrinologists about the consequences of hypercortisolism can be beneficial in bridging the gap between academic and community settings
Lewis Blevins, MD | Richard Auchus, MD, PhD
| David Brown, MD, PhD
|
Amir Hamrahian, MD | Smita Kargutkar, MD |
Click HERE to read the supplement.
©2022 Corcept Therapeutics Incorporated. All Rights Reserved. DSE-00997 DEC 2022